TY  - JOUR
T1  - Error in financial disclosure in: Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses
Y1  - 2009/02/09
N1  - 10.1001/archinternmed.2008.614
JO  - Archives of Internal Medicine
SP  - 304
EP  - 304
VL  - 169
IS  - 3
N2  - 
“Financial Disclosure: Dr Keitel has received research support from Protein Sciences Inc and Novartis Vaccines. Dr Nichol has served as a consultant for the influenza vaccine manufacturers sanofi pasteur, GlaxoSmithKline Biologicals, CSL Biotherapies, Novartis, and MedImmune and has received research funding from sanofi pasteur and GlaxoSmithKline Biologicals. Dr Treanor has received research support from Protein Sciences, Merck, Wyeth, GlaxoSmithKline, Antigen Express, Mercia Pharma, VaxInnate, Ligocyte, Sanofi, and CSL Biotherapies; has served as a consultant/scientific advisory board member for AlphaVax, Epimmune, Dynavax, Immune Targeting Systems, Pulmatrix, Powdermed, PaxVax, and Toyama; and has served as a Data Safety Monitoring Board member for Medimmune and Novavax.”

SN  - 0003-9926
M3  - doi: 10.1001/archinternmed.2008.614
UR  - http://dx.doi.org/10.1001/archinternmed.2008.614
ER  -